BACKGROUND: Lack of consensus regarding how to identify cancer patients with significant fatigue has hampered research regarding cancer-related fatigue (CRF). METHODS: Specific criteria were used to identify CRF cases in women with stage 0-II breast cancer (BC group, n = 304). Women completed assessments before adjuvant therapy (baseline), end of adjuvant therapy (Post-Tx), and 6 and 42 months after end of adjuvant therapy (6 and 42 Month Post-Tx). At each, women completed a clinical interview and questionnaires assessing physical and mental health. A healthy control (HC) group with no history of BC (n = 337) completed 2 similar assessments 36 months apart. RESULTS: Off-treatment CRF prevalence was 9% and 13% at the 6 and 42 Month Post-Tx assessments, respectively. Thus, 15% of the sample evidenced off-treatment CRF with 7% evidencing delayed onset CRF. CRF at the 6 Month Post-Tx assessment was associated only with CRF at baseline (OR = 3.2) and Post-Tx assessments (OR = 3.9). CRF at the 42 Month Post-Tx assessment was associated with CRF at the Post-Tx assessment (OR = 6.1), obesity at baseline, and several baseline measures of coping in response to fatigue. Off-treatment CRF cases differed markedly from CRF noncases and healthy controls on a spectrum of health status indices (mean effect size >1.0 SD). CONCLUSIONS: Results document the prevalence of off-treatment and delayed onset CRF, suggest the utility of a cognitive-behavioral model of CRF, and support NCCN guidelines recommending monitoring fatigue across the cancer trajectory.
BACKGROUND: Lack of consensus regarding how to identify cancerpatients with significant fatigue has hampered research regarding cancer-related fatigue (CRF). METHODS: Specific criteria were used to identify CRF cases in women with stage 0-II breast cancer (BC group, n = 304). Women completed assessments before adjuvant therapy (baseline), end of adjuvant therapy (Post-Tx), and 6 and 42 months after end of adjuvant therapy (6 and 42 Month Post-Tx). At each, women completed a clinical interview and questionnaires assessing physical and mental health. A healthy control (HC) group with no history of BC (n = 337) completed 2 similar assessments 36 months apart. RESULTS: Off-treatment CRF prevalence was 9% and 13% at the 6 and 42 Month Post-Tx assessments, respectively. Thus, 15% of the sample evidenced off-treatment CRF with 7% evidencing delayed onset CRF. CRF at the 6 Month Post-Tx assessment was associated only with CRF at baseline (OR = 3.2) and Post-Tx assessments (OR = 3.9). CRF at the 42 Month Post-Tx assessment was associated with CRF at the Post-Tx assessment (OR = 6.1), obesity at baseline, and several baseline measures of coping in response to fatigue. Off-treatment CRF cases differed markedly from CRF noncases and healthy controls on a spectrum of health status indices (mean effect size >1.0 SD). CONCLUSIONS: Results document the prevalence of off-treatment and delayed onset CRF, suggest the utility of a cognitive-behavioral model of CRF, and support NCCN guidelines recommending monitoring fatigue across the cancer trajectory.
Authors: Kerry S Courneya; John R Mackey; Gordon J Bell; Lee W Jones; Catherine J Field; Adrian S Fairey Journal: J Clin Oncol Date: 2003-05-01 Impact factor: 44.544
Authors: D M Hann; P B Jacobsen; L M Azzarello; S C Martin; S L Curran; K K Fields; H Greenberg; G Lyman Journal: Qual Life Res Date: 1998-05 Impact factor: 4.147
Authors: Kathryn H Schmitz; Marian L Neuhouser; Tanya Agurs-Collins; Krista A Zanetti; Lisa Cadmus-Bertram; Lorraine T Dean; Bettina F Drake Journal: J Natl Cancer Inst Date: 2013-08-29 Impact factor: 13.506
Authors: Julia E Inglis; Michelle C Janelsins; Eva Culakova; Karen M Mustian; Po-Ju Lin; Ian R Kleckner; Luke J Peppone Journal: Support Care Cancer Date: 2019-07-02 Impact factor: 3.603
Authors: D Howell; S Keller-Olaman; T K Oliver; T F Hack; L Broadfield; K Biggs; J Chung; D Gravelle; E Green; M Hamel; T Harth; P Johnston; D McLeod; N Swinton; A Syme; K Olson Journal: Curr Oncol Date: 2013-06 Impact factor: 3.677
Authors: Hamza Abid; Kord M Kober; Betty Smoot; Steven M Paul; Marilyn Hammer; Jon D Levine; Kathryn Lee; Fay Wright; Bruce A Cooper; Yvette P Conley; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2017-01-04 Impact factor: 3.612
Authors: Guy H Montgomery; Daniel David; Maria Kangas; Sheryl Green; Madalina Sucala; Dana H Bovbjerg; Michael N Hallquist; Julie B Schnur Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: Andrea M Barsevick; Michael R Irwin; Pamela Hinds; Andrew Miller; Ann Berger; Paul Jacobsen; Sonia Ancoli-Israel; Bryce B Reeve; Karen Mustian; Ann O'Mara; Jin-Shei Lai; Michael Fisch; David Cella Journal: J Natl Cancer Inst Date: 2013-09-18 Impact factor: 13.506
Authors: J L Vardy; H M Dhillon; G R Pond; C Renton; A Dodd; H Zhang; S J Clarke; I F Tannock Journal: Ann Oncol Date: 2016-07-20 Impact factor: 32.976